Last reviewed · How we verify

NCT03968510

Swalqol in Primary Hyperparathyroidism

Completed Last updated 4 June 2021
What this trial tests

trial testing parathyroidectomy in Hyperparathyroidism in 150 participants. Completed in 1 November 2020.

Timeline
1 November 2018
Primary endpoint
1 July 2020
1 November 2020

Quick facts

Lead sponsorUşak University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment150
Start date1 November 2018
Primary completion1 July 2020
Estimated completion1 November 2020
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Uşak University

Who can join

Eligibility, any sex, with Hyperparathyroidism. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Swallow related quality of life before and after parathyroidectomy will be evaluated in patients with primary hyperparathyridism.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of parathyroidectomy

Trials testing the same drug.

Other recruiting trials for Hyperparathyroidism

Currently open trials in the same condition.

Other Uşak University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03968510.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing